GRANULES Granules India Q1 FY26 results (Apr–Jun 2025) and concall
Granules India reported a modest revenue growth in Q1 FY26, driven by the consolidation of Senn Chemicals AG and initial ramp-up of new facilities. Despite strong gross margin expansion, EBITDA saw a slight decline due to increased professional expenses for remediation and higher manpower costs from the acquisition. The company is in the final stages of FDA remediation for its Gagillapur facility and successfully completed inspections for its new Genome Valley and API Unit I facilities, positioning for accelerated growth from FY27. A significant strategic move was the foray into high-growth pe
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 568 | 842 | 768 | 810 |
| EBITDA | 103 | 168 | 117 | 144 |
| Net profit | 41 | 90 | 94 | 69 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
